Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A
Almost a year after inking a billion-dollar biobucks deal with Bristol Myers Squibb, NYC biotech Volastra Therapeutics is linking up with two other pharma giants in a one-two combo — involving an in-licensing and some cash from well-known investors to keep its work moving.
Volastra put out word Tuesday morning that it has finished in-licensing sovilnesib from Amgen. Sovilnesib, also known as AMG 650, is an oral inhibitor of KIF18A, one of the targets that Volastra has focused on in its pursuit of chromosomal instability. The deal gives Volastra an exclusive license to develop and commercialize the drug anywhere worldwide except for China.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.